Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

Autor: Åsa Ericsson, Johan Jendle, Emelie Andersson, Nino Hallén, Katarina Steen Carlsson, Peter Lindgren, Desirée Thielke, Sofie Persson

Publikováno v: Diabetologia

Aims/hypothesis The risk of complications and medical consequences of type 2 diabetes are well known. Hospital costs have been identified as a key driver of total costs in studies of the economic burden of type 2 diabetes. Less evidence has been gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce9723e06511b7ac83bd9957314218c5
https://doi.org/10.1007/s00125-020-05277-3

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

Autor: Andrei Mircea Catarig, Carel W. le Roux, Ildiko Lingvay, Rory J. McCrimmon, Juan P. Frias, Desirée Thielke, Nanna L. Lausvig

Publikováno v: Diabetologia

Aims/hypothesis Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60b80cf3e162bd6ac235c63ef0a499f4
https://doi.org/10.1007/s00125-019-05065-8

Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes

Autor: John B. Buse, Richard E. Pratley, Kajsa Kvist, Ingrid Holst, Filip K. Knop, Desirée Thielke

Publikováno v: Diabetes, Obesity & Metabolism
Buse, J B, Holst, I, Knop, F K, Kvist, K, Thielke, D & Pratley, R 2021, ' Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes ', Diabetes, Obesity and Metabolism, vol. 23, no. 7, pp. 1666-1671 . https://doi.org/10.1111/dom.14381

Data‐driven tools are needed to inform individualized treatment decisions for people with type 2 diabetes (T2D). To show how treatment might be individualized, an interactive outline tool was developed to predict treatment outcomes. Individualized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad6f0ba9286903e6449ddc511ac33dd6
https://pubmed.ncbi.nlm.nih.gov/33764641

Author response for 'Days absent from work due to complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden'

Autor: Brian Larsen Thorsted, Peter Lindgren, Johan Jendle, Emelie Andersson, Pierre Johansen, Sofie Persson, Desirée Thielke, Katarina Steen Carlsson

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07f3858a3a74b6a1317d552cac39fed
https://doi.org/10.1111/dom.14070/v2/response1

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Autor: Andrei Mircea Catarig, Nanna L. Lausvig, Ildiko Lingvay, Harish Kumar, Carel W. le Roux, Desirée Thielke, Adie Viljoen, Juan P. Frias, Rory J. McCrimmon

Publikováno v: The lancet. Diabetesendocrinology. 7(11)

Summary Background Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71fb8224894fccf73699457666b5d5ef
https://pubmed.ncbi.nlm.nih.gov/31540866